Satellite Banner
Technology Networks Header
Wednesday, September 17, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Ovarian Cancer Oncogene Found in "Junk DNA"
The study is published online in this week in Cancer Cell.
New Genetic Target for a Different Kind of Cancer Drug
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that is drastically reduced in human lung and breast cancer cells.
Combination microRNA Therapy Suppresses Non-Small-Cell Lung Cancer
Findings offer a promising therapeutic avenue for NSCLC.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
New Gene Mutations for Wilms Tumor
UT Southwestern researchers identified the mutated genes by sequencing the DNA of 44 tumors.
New Sequence of Naked Mole Rat Genome Facilitates Cancer Resistance Research
Director of Science at The Genome Analysis Centre (TGAC) Federica Di Palma co-authors new genetic study on the naked mole rat’s resistance to cancer, identifying key genomic variations that may have contributed to the evolution of this extraordinary species.
Repressing the Repressors May Drive Tissue-Specific Cancers
Stowers scientists establish Drosophila and mammalian models to study mutations found in pediatric brain tumors.
Scroll Up
Scroll Down
Return
Non Viral Reagent for Efficient siRNA Delivery
Anne-Laure Bolcato-Bellemin, In vivo Research Manager, Polyplus-transfection, speaking at RNAi World Congress 2009
Date Posted: Monday, November 02, 2009
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes
Polyplus-transfection SA, a privately-held company developing innovative solutions for the delivery of nucleic acids in research, bioproduction and therapy, announced today that it has granted Roche Glycart AG, a Swiss biotechnology company fully-owned by Roche, a non exclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes.
Monday, January 24, 2011
Genethon to Use Polyplus-transfection’s jetPEI™ Transfection Reagent for Producing Viral Vectors
Genethon will use the jetPEI transfection reagent in the process of developing gene therapies for the treatment of rare diseases.
Friday, September 10, 2010
Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds
New money will fund the company’s RNAplus research program and strengthen its human and material resources.
Friday, December 11, 2009
Polyplus-transfection Unveils Technology to Improve Intracellular Delivery of Small Interfering RNAs In-vivo
The "Sticky siRNA" technology is already being tested in vivo by academic laboratories and biotech companies.
Friday, April 25, 2008
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv